Trulieve Cannabis (TRUL) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
22 May, 2026Executive summary
Second quarter 2025 revenue was $302 million, stable year-over-year, with 94% from retail sales and a gross margin of 61%; adjusted EBITDA was $111 million (37% margin), up 3% year-over-year, reflecting disciplined expense control and operational efficiency.
Net loss attributable to common shareholders was $14 million; adjusted net loss was $8 million, excluding non-recurring items.
Retail traffic and units sold increased 8% and 9% year-over-year, offset by pricing compression and loyalty point redemption; over 12.5 million branded products sold in Q2, with loyalty program members exceeding 725,000 and accounting for 71% of transactions.
Wholesale revenue grew 27% year-over-year, with expanded relationships in Maryland, Pennsylvania, and Ohio, and continued focus on branded products, distribution, and customer experience.
Cash flow from operations was $86 million for the quarter, with free cash flow at $75 million.
Financial highlights
Gross profit was $183 million (61% margin), up 1% year-over-year; SG&A expenses were $101 million (33% of revenue), comparable to last year.
Retail revenue was $284 million, down 2% year-over-year but up 1% sequentially; wholesale revenue rose 27% year-over-year and 11% sequentially.
Net loss was $14 million, compared to a $12 million loss last year; adjusted net loss was $8 million, excluding non-recurring charges.
Adjusted EBITDA margin improved to 37% from 35% in the prior year.
Cash at quarter end was $401 million; debt totaled $478 million at 7.9% interest.
Outlook and guidance
Third quarter revenue expected to decline mid-single digits sequentially due to seasonality; full-year gross margin expected to remain around 60%.
Full-year cash flow from operations projected at least $250 million, with capital expenditures up to $40 million.
Guidance may be revised later in the year depending on macroeconomic conditions and reform progress.
Management emphasized progress on the 2025 plan, focusing on customers, distribution, branded products, and reform.
The company is positioned for industry leadership with strong margins, cash flow, and operational scale.
Latest events from Trulieve Cannabis
- Vote set on Delaware move to align with U.S. operations; board urges approval, no dilution expected.TRUL
Proxy filing12 Jun 2026 - Market leader in U.S. medical cannabis, poised for growth with NYSE listing and tax relief.TRUL
Investor presentation7 Jun 2026 - 2024 revenue up 5% to $1.2B, with record cash flow and ongoing IRS 280E tax challenge.TRUL
Q4 202422 May 2026 - Q1 revenue hit $287M with 59% margin, $100M EBITDA, and regulatory changes fueling growth.TRUL
Q1 20267 May 2026 - 2025 revenue hit $1.2B with 60% gross margin, record EBITDA, and strong cash flow.TRUL
Q4 202526 Feb 2026 - Q2 revenue hit $303M, margins expanded, and tax uncertainties remain a key risk.TRUL
Q2 20242 Feb 2026 - Strong Q2 retail growth, robust loyalty adoption, and Florida poised for rapid adult-use expansion.TRUL
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase2 Feb 2026 - Q3 revenue up 3% to $284M, 61% gross margin, $96M adjusted EBITDA, net loss $60M.TRUL
Q3 202416 Jan 2026 - Retail expansion, operational efficiency, and customer focus drive growth amid evolving regulations.TRUL
27th Annual Needham Growth Conference10 Jan 2026